About Raptor Pharmaceutical (NASDAQ:RPTP)
Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-77.01%
Return on Assets-15.64%
Raptor Pharmaceutical (NASDAQ:RPTP) Frequently Asked Questions
What is Raptor Pharmaceutical's stock symbol?
Raptor Pharmaceutical trades on the NASDAQ under the ticker symbol "RPTP."
How were Raptor Pharmaceutical's earnings last quarter?
Raptor Pharmaceutical Corp (NASDAQ:RPTP) posted its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.02. The biotechnology company had revenue of $32.05 million for the quarter, compared to analyst estimates of $28.52 million. Raptor Pharmaceutical had a negative return on equity of 77.01% and a negative net margin of 43.75%. The business's quarterly revenue was up 37.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.17) EPS. View Raptor Pharmaceutical's Earnings History.
Who are some of Raptor Pharmaceutical's key competitors?
Some companies that are related to Raptor Pharmaceutical include Sangamo Therapeutics (SGMO), Radius Health (RDUS), Myokardia (MYOK), Ascendis Pharma A/S (ASND), Clinigen Group (CLIN), Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Lexicon Pharmaceuticals (LXRX), Dermira (DERM), Ignyta (RXDX), Xencor (XNCR), Neuroderm (NDRM), Madrigal Pharmaceuticals (MDGL), Regenxbio (RGNX), Acorda Therapeutics (ACOR), Flexion Therapeutics (FLXN), Omeros (OMER) and Athenex (ATNX).
How do I buy Raptor Pharmaceutical stock?
Shares of Raptor Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Raptor Pharmaceutical's stock price today?
One share of Raptor Pharmaceutical stock can currently be purchased for approximately $9.00.
How big of a company is Raptor Pharmaceutical?
Raptor Pharmaceutical has a market capitalization of $767.76 million. Raptor Pharmaceutical employs 158 workers across the globe.
How can I contact Raptor Pharmaceutical?
Raptor Pharmaceutical's mailing address is 7 Hamilton Lndg Ste 100, NOVATO, CA 94949-8283, United States. The biotechnology company can be reached via phone at +1-415-4086200.
MarketBeat Community Rating for Raptor Pharmaceutical (RPTP)MarketBeat's community ratings are surveys of what our community members think about Raptor Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Raptor Pharmaceutical (NASDAQ:RPTP) Earnings History and Estimates Chart
Raptor Pharmaceutical (NASDAQ RPTP) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/4/2016||Q216||($0.18)||($0.16)||$28.52 million||$32.05 million||View||Listen|
|5/5/2016||Q116||($0.17)||($0.17)||$27.17 million||$27.47 million||View||N/A|
|2/25/2016||Q415||($0.19)||($0.17)||$26.08 million||$24.67 million||View||Listen|
|11/5/2015||Q315||($0.18)||($0.18)||$24.25 million||$25.80 million||View||Listen|
|8/6/2015||Q215||($0.21)||($0.12)||$21.40 million||$23.30 million||View||N/A|
|5/7/2015||Q115||($0.25)||($0.24)||$19.10 million||$20.50 million||View||N/A|
|2/26/2015||Q414||($0.14)||($0.25)||$20.12 million||$17.30 million||View||N/A|
|11/6/2014||Q314||($0.18)||($0.04)||$18.90 million||$23.80 million||View||N/A|
|8/7/2014||Q214||($0.19)||($0.15)||$14.58 million||$16.31 million||View||N/A|
|5/8/2014||Q413||($0.17)||($0.20)||$11.81 million||$12.10 million||View||N/A|
|3/13/2014||Q313||($0.18)||($0.19)||$8.99 million||$10.25 million||View||N/A|
|1/9/2013||Q1 2013||($0.23)||($0.26)||$0.25 million||View||N/A|
Raptor Pharmaceutical (NASDAQ:RPTP) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Raptor Pharmaceutical (NASDAQ:RPTP)
No dividend announcements for this company have been tracked by MarketBeat.com
Raptor Pharmaceutical (NASDAQ RPTP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 54.88%
Raptor Pharmaceutical (NASDAQ RPTP) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/9/2015||Suzanne Louise Bruhn||Director||Sell||18,258||$12.47||$227,677.26|| |
|9/2/2015||Raymond Anderson||Director||Sell||4,916||$12.51||$61,499.16|| |
|8/31/2015||Raymond Anderson||Director||Sell||8,084||$12.52||$101,211.68|| |
|7/1/2015||Llew Keltner||Director||Sell||50,000||$16.05||$802,500.00|| |
|6/18/2015||Thomas E Daley||Insider||Sell||35,000||$15.00||$525,000.00|| |
|6/10/2015||Suzanne Louise Bruhn||Director||Sell||30,000||$13.45||$403,500.00|| |
|5/4/2015||Richard L Franklin||Director||Sell||10,000||$9.61||$96,100.00|| |
|4/2/2015||Richard L Franklin||Director||Sell||10,000||$10.37||$103,700.00|| |
|3/23/2015||Christopher M Starr||Director||Sell||20,033||$11.62||$232,783.46|| |
|3/2/2015||Richard L Franklin||Director||Sell||10,000||$9.18||$91,800.00|| |
|2/24/2015||Christopher M Starr||Director||Sell||30,000||$9.52||$285,600.00|| |
|2/2/2015||Richard L Franklin||Director||Sell||7,109||$9.20||$65,402.80|| |
|1/22/2015||Christopher M Starr||Director||Sell||30,000||$9.45||$283,500.00|| |
|1/15/2015||Christopher M Starr||Director||Sell||30,000||$9.73||$291,900.00|| |
|1/12/2015||Raymond Anderson||Director||Sell||10,000||$10.58||$105,800.00|| |
|12/22/2014||Christopher M Starr||CEO||Sell||30,000||$9.00||$270,000.00|| |
|12/15/2014||Christopher M Starr||CEO||Sell||30,000||$8.15||$244,500.00|| |
|11/24/2014||Christopher M Starr||CEO||Sell||30,000||$9.97||$299,100.00|| |
|10/22/2014||Christopher M Starr||CEO||Sell||30,000||$10.25||$307,500.00|| |
|9/23/2014||Christopher M Starr||CEO||Sell||30,000||$10.21||$306,300.00|| |
|9/16/2014||Christopher M Starr||CEO||Sell||32,896||$10.60||$348,697.60|| |
|9/10/2014||Raymond Anderson||Director||Sell||10,000||$10.81||$108,100.00|| |
|8/25/2014||Erich Sager||Director||Sell||10,000||$11.01||$110,100.00|| |
|7/7/2014||Llew Keltner||Director||Sell||10,000||$11.21||$112,100.00|| |
|5/13/2014||Georgia Erbez||CFO||Buy||16,100||$7.90||$127,190.00|| |
|4/7/2014||Vijay Samant||Director||Sell||5,000||$8.59||$42,950.00|| |
|3/17/2014||Christopher Starr||CEO||Sell||19,316||$10.79||$208,419.64|| |
|1/13/2014||Timothy Walbert||Director||Sell||5,520||$15.06||$83,131.20|| |
|1/9/2014||Thomas Daley||Insider||Sell||15,000||$14.17||$212,550.00|| |
|1/7/2014||Llew Keltner||Director||Sell||10,000||$13.25||$132,500.00|| |
|1/2/2014||Richard Franklin||Director||Sell||10,715||$13.12||$140,580.80|| |
|12/9/2013||Vijay Samant||Director||Sell||5,000||$13.86||$69,300.00|| |
|11/13/2013||Timothy Walbert||Director||Sell||5,521||$12.44||$68,681.24|| |
|11/4/2013||Richard Franklin||Director||Sell||10,715||$14.88||$159,439.20|| |
|10/15/2013||Christopher M Starr||CEO||Sell||25,000||$13.77||$344,250.00|| |
|10/14/2013||Suzanne Louise Bruhn||Director||Sell||2,760||$13.58||$37,480.80|| |
|10/7/2013||Vijay Samant||Director||Sell||5,000||$14.76||$73,800.00|| |
|9/16/2013||Christopher Starr||CEO||Sell||25,000||$14.21||$355,250.00|| |
|9/16/2013||Erich Sager||Director||Sell||17,000||$14.21||$241,570.00|| |
|9/13/2013||Suzanne Louise Bruhn||Director||Sell||2,760||$14.07||$38,833.20|| |
|9/9/2013||Richard L Franklin||Director||Sell||10,715||$14.24||$152,581.60|| |
|9/9/2013||Thomas E Daley||Insider||Sell||25,000||$14.28||$357,000.00|| |
|8/30/2013||Georgia Erbez||CFO||Sell||7,400||$13.42||$99,308.00|| |
|12/28/2012||Raymond Anderson||Director||Sell||2,000||$5.50||$11,000.00|| |
|11/26/2012||Erich Sager||Director||Sell||11,279||$5.00||$56,395.00|| |
|9/12/2012||Raymond Anderson||Director||Sell||2,000||$5.50||$11,000.00|| |
Raptor Pharmaceutical (NASDAQ RPTP) News Headlines
|Adamas Pharmaceuticals, Inc.: Substantial Upside For A Misunderstood Drug Maker|
seekingalpha.com - November 1 at 3:18 PM
|Reviewing Raptor Pharmaceutical Corp (RPTP) and Its Peers|
www.americanbankingnews.com - September 24 at 6:18 PM
|Head to Head Review: Raptor Pharmaceutical Corp (RPTP) vs. Prothena Corporation PLC (PRTA)|
www.americanbankingnews.com - August 28 at 2:24 PM
|RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Art|
biz.yahoo.com - October 31 at 7:29 AM
|Horizon Pharma (HZNP) Announces Completion of Raptor Pharma (RPTP) Acquisition|
www.streetinsider.com - October 26 at 10:37 AM
|RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisit|
biz.yahoo.com - October 25 at 7:08 PM
|Horizon Pharma (HZNP) Announces Completion of Raptor Pharma (RPTP) Acquisition - StreetInsider.com|
www.streetinsider.com - October 25 at 12:18 PM
|How These Biotech Stocks are Faring? -- Raptor Pharma, Amicus Therapeutics, Neuralstem, and Macrocure|
www.marketwatch.com - October 21 at 7:10 PM
|RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - October 20 at 8:37 AM
|RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material|
biz.yahoo.com - October 11 at 7:28 PM
|Horizon Pharma: Another Core Plus Biotech Worth Buying|
seekingalpha.com - September 28 at 12:19 PM
Raptor Pharmaceutical (NASDAQ:RPTP) SEC Filings
Raptor Pharmaceutical (NASDAQ:RPTP) Income Statement, Balance Sheet and Cash Flow Statement
Raptor Pharmaceutical (NASDAQ RPTP) Stock Chart for Monday, December, 11, 2017